Bone marrow mesenchymal stromal cells to treat complications following allogeneic stem cell transplantation

Tissue Engineering - Part B: Reviews

Volumn 20, Issue 3, 2014, Pages 211-217

  Battiwalla, Minoo ^a   Barrett, A John ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; FLOWCHARTING; PATHOLOGY; STEM CELLS;

BONE MARROW MESENCHYMAL; BONE MARROW STROMAL CELLS; CLINICAL TRIAL DESIGNS; GRAFT-VERSUS-HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL RESPONSE; MESENCHYMAL STROMAL CELLS; STEM CELL TRANSPLANTATION;

CELL CULTURE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL FATE; CELL PROLIFERATION; GRAFT VERSUS HOST REACTION; HUMAN; MESENCHYME CELL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; STROMA CELL; ALLOGRAFT; EVIDENCE BASED MEDICINE; GRAFT REJECTION; IMMUNOLOGY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PATHOLOGY; PROCEDURES; STEM CELL TRANSPLANTATION; TRANSPLANTATION; TREATMENT OUTCOME;

ALLOGRAFTS; CELL DIFFERENTIATION; EVIDENCE-BASED MEDICINE; GRAFT REJECTION; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84901378544     PISSN: 19373368     EISSN: 19373376     Source Type: Journal    
DOI: 10.1089/ten.teb.2013.0566     Document Type: Article

References (55)

1. Westin, J.R., Saliba, R.M., De Lima, M., Alousi, A., Hosing, C., Qazilbash, M.H., et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011, 601953, 2011.
2. Friedenstein, A.J., Petrakova, K.V., Kurolesova, A.I., and Frolova, G.P. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6, 230, 1968.
3. Bensidhoum, M., Chapel, A., Francois, S., Demarquay, C., Mazurier, C., Fouillard, L., et al. Homing of in vitro expanded Stro-1- or Stro-1 + human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. Blood 103, 3313, 2004.
4. Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143, 1999.
5. Wu, J.Y., Scadden, D.T., and Kronenberg, H.M. Role of the osteoblast lineage in the bone marrow hematopoietic niches. J Bone Miner Res 24, 759, 2009.
6. Caplan, A.I. Mesenchymal stem cells. J Orthop Res 9, 641, 1991.
7. Koc, O.N., Peters, C., Aubourg, P., Raghavan, S., Dyhouse, S., De Gasperi, R., et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 27, 1675, 1999.
8. Rieger, K., Marinets, O., Fietz, T., Korper, S., Sommer, D., Mucke, C., et al. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. Exp Hematol 33, 605, 2005.
9. Awaya, N., Rupert, K., Bryant, E., and Torok-Storb, B. Failure of adult marrow-derived stem cells to generate marrow stroma after successful hematopoietic stem cell transplantation. Exp Hematol 30, 937, 2002.
10. Joo, S.Y., Cho, K.A., Jung, Y.J., Kim, H.S., Park, S.Y., Choi, Y.B., et al. Bioimaging for the monitoring of the in vivo distribution of infused mesenchymal stem cells in a mouse model of the graft-versus-host reaction. Cell Biol Int 35, 417, 2011.
11. Gao, J., Dennis, J.E., Muzic, R.F., Lundberg, M., and Caplan, A.I. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 169, 12, 2001.
12. Kebriaei, P., and Robinson, S. Treatment of graft-versushost-disease with mesenchymal stromal cells. Cytotherapy 13, 262, 2011.
13. Polchert, D., Sobinsky, J., Douglas, G., Kidd, M., Moadsiri, A., Reina, E., et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol 38, 1745, 2008.
14. Jang, M.J., Kim, H.S., Lee, H.G., Kim, G.J., Jeon, H.G., Shin, H.S., et al. Placenta-derived mesenchymal stem cells have an immunomodulatory effect that can control acute graft-versus-host disease in mice. Acta Haematol 129, 197, 2013.
15. Gregoire-Gauthier, J., Selleri, S., Fontaine, F., Dieng, M.M., Patey, N., Despars, G., et al. Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute graft-versus-host disease in a xenogenic mouse model. Stem Cells Dev 21, 1616, 2012.
16. Tisato, V., Naresh, K., Girdlestone, J., Navarrete, C., and Dazzi, F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia 21, 1992, 2007.
17. Sudres, M., Norol, F., Trenado, A., Gregoire, S., Charlotte, F., Levacher, B., et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 176, 7761, 2006.
18. Zinocker, S., Wang, M.Y., Rolstad, B., and Vaage, J.T. Mesenchymal stromal cells fail to alleviate experimental graft-versus-host disease in rats transplanted with major histocompatibility complex-mismatched bone marrow. Scand J Immunol 76, 464, 2012.
19. Bruck, F., Belle, L., Lechanteur, C., de Leval, L., Hannon, M., Dubois, S., et al. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease. Cytotherapy 15, 267, 2013.
20. Noort, W.A., Kruisselbrink, A.B., in't Anker, P.S., Kruger, M., van Bezooijen, R.L., de Paus, R.A., et al. Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 30, 870, 2002.
21. Devine, S.M., Bartholomew, A.M., Mahmud, N., Nelson, M., Patil, S., Hardy, W., et al. Mesenchymal stem cells are capable of homing to the bonemarrow of non-human primates following systemic infusion. Exp Hematol 29, 244, 2001.
22. Mouiseddine, M., Francois, S., Semont, A., Sache, A., Allenet, B., Mathieu, N., et al. Human mesenchymal stem cells home specifically to radiation-injured tissues in a nonobese diabetes/severe combined immunodeficiency mouse model. Br J Radiol 80, Spec No 1:S49, 2007.
23. Uccelli, A., Pistoia, V., and Moretta, L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 28, 219, 2007.
24. Le Blanc, K., and Ringden, O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11, 321, 2005.
25. Prockop, D.J., and Olson, S.D. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood 109, 3147, 2007.
26. Tse, W.T., Pendleton, J.D., Beyer, W.M., Egalka, M.C., and Guinan, E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389, 2003.
27. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., and Ringden, O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31, 890, 2003.
28. Klyushnenkova, E., Mosca, J.D., Zernetkina, V., Majumdar, M.K., Beggs, K.J., Simonetti, D.W., et al. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12, 47, 2005.
29. Rasmusson, I., Ringden, O., Sundberg, B., and Le Blanc, K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76, 1208, 2003.
30. Nauta, A.J., and Fibbe, W.E. Immunomodulatory properties of mesenchymal stromal cells. Blood 110, 3499, 2007.
31. Sundin, M., Barrett, A.J., Ringden, O., Uzunel, M., Lonnies, H., Dackland, A.L., et al. HSCT recipients have specific tolerance to MSC but not to the MSC donor. J Immunother 32, 755, 2009.
32. Siegel, G., Schafer, R., and Dazzi, F. The immunosuppressive properties of mesenchymal stem cells. Transplantation 87, S45, 2009.
33. Jitschin, R., Mougiakakos, D., Von Bahr, L., Volkl, S., Moll, G., Ringden, O., et al. Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem-cell transplantation. Stem Cells 31, 1715, 2013.
34. Le Blanc, K., Gotherstrom, C., Ringden, O., Hassan, M., McMahon, R., Horwitz, E., et al. Fetal mesenchymal stemcell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 79, 1607, 2005.
35. Keating, A. Mesenchymal stromal cells. Curr Opin Hematol 13, 419, 2006.
36. Herdrich, B.J., Lind, R.C., and Liechty, K.W. Multipotent adult progenitor cells: their role in wound healing and the treatment of dermal wounds. Cytotherapy 10, 543, 2008.
37. Semont, A., Francois, S., Mouiseddine, M., Francois, A., Sache, A., Frick, J., et al. Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury. Adv Exp Med Biol 585, 19, 2006.
38. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315, 2006.
39. Ren, J., Jin, P., Sabatino, M., Balakumaran, A., Feng, J., Kuznetsov, S.A., et al. Global transcriptome analysis of human bone marrow stromal cells (BMSC) reveals proliferative, mobile and interactive cells that produce abundant extracellular matrix proteins, some of which may affect BMSC potency. Cytotherapy 13, 661, 2011.
40. Izadpanah, R., Kaushal, D., Kriedt, C., Tsien, F., Patel, B., Dufour, J., et al. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells. Cancer Res 68, 4229, 2008.
41. Tolar, J., Nauta, A.J., Osborn, M.J., Panoskaltsis Mortari, A., McElmurry, R.T., Bell, S., et al. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells 25, 371, 2007.
42. Larson, B.L., Ylostalo, J., Lee, R.H., Gregory, C., and Prockop, D.J. Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells. Tissue Eng Part A 16, 3385, 2010.
43. Larson, B.L., Ylostalo, J., and Prockop, D.J. Human multipotent stromal cells undergo sharp transition from division to development in culture. Stem Cells 26, 193, 2008.
44. von Bahr, L., Sundberg, B., Lonnies, L., Sander, B., Karbach, H., Hagglund, H., et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 18, 557, 2012.
45. Battiwalla, M., and Barrett, A.J. Safety Issues in MSC Therapy. In: Hematti, P., Keating, A., eds. Mesenchymal Stromal Cell. New York: Springer, 2013, pp. 377-387.
46. Ning, H., Yang, F., Jiang, M., Hu, L., Feng, K., Zhang, J., et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22, 593, 2008.
47. Behre, G., Theurich, S., Weber, T., and Christopeit, M. Reply to 'The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rates in hematologic malignancy patients: outcome of a pilot clinical study' by Ning et al. Leukemia 23, 178; author reply 9, 2009.
48. Battiwalla, M., and Hematti, P. Mesenchymal stem cells in hematopoietic stem cell transplantation. Cytotherapy 11, 503, 2009.
49. Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371, 1579, 2008.
50. Le Blanc, K., Rasmusson, I., Sundberg, B., Gotherstrom, C., Hassan, M., Uzunel, M., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439, 2004.
51. Prasad, V.K., Lucas, K.G., Kleiner, G.I., Talano, J.A., Jacobsohn, D., Broadwater, G., et al. Efficacy and safety of ex-vivo cultured adult human mesenchymal stem cells (Prochymal(TM)) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant 17, 534, 2011.
52. Ringden, O., Uzunel, M., Sundberg, B., Lonnies, L., Nava, S., Gustafsson, J., et al. Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. Leukemia 21, 2271, 2007.
53. Galipeau, J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Cytotherapy 15, 2, 2012.
54. Sabatino, M., Ren, J., David-Ocampo, V., England, L., McGann, M., Tran, M., et al. The establishment of a bank of stored clinical bone marrow stromal cell products. J Transl Med 10, 23, 2013.
55. Paczesny, S. Discovery and validation of graft-versus-host disease biomarkers. Blood 121, 585, 2013.